NCI Definition: A WHO grade I slow growing tumor, more frequently affecting young adults. It is composed of small, uniform, mature cells resembling pineocytes with occasional large pineocytomatous rosettes. It may show a wide range of divergent phenotypes, including neuronal, glial, melanocytic, photoreceptor and mesenchymal differentiation. Pineocytoma generally has a relatively favorable prognosis. (Adapted from WHO) 
There is 1 clinical trial for pineocytoma, of which 1 is open and 0 are completed or closed. Of the trial that contains pineocytoma as an inclusion criterion, 1 is phase 2 (1 open).
Nivolumab is the most common intervention in pineocytoma clinical trials.
Significant Genes in Pineocytoma
H3F3A is an inclusion eligibility criterion in 1 clinical trial for pineocytoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and pineocytoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.